

INDEX

	Contents	Page No.
SECTION I		
Chapter 1	Introduction	
1.1	Introduction	1
1.2	Objectives of work	6
1.3	References	7
1.4	Materials	8
Chapter 2	Literature Review	
2.1	Migraine	10
2.1.1	Migraine Pathophysiology	10
2.1.2	Serotonin (5-HT) receptors and migraine treatment	13
2.1.3	Drugs for the acute treatment of migraine	14
2.1.4	Pharmacology and Mechanisms of Action of triptans	15
2.1.5	Side effects of Triptans	17
2.1.6	Need for mucoadhesive nasal drug delivery system	17
2.1.7	for sumatriptan	
2.2	Nasal Delivery System	18
2.2.1	Introduction	18
2.2.2	Nasal cavity	19
2.2.3	Factors influencing absorption of drugs across nasal epithelium	21
2.2.4	Olfactory region	22
2.2.5	Transport Mechanisms along olfactory pathway	23
2.2.6	Factors affecting transport across olfactory epithelium	23
2.2.7	Approaches to enhance nasal drug absorption	23
2.2.8	Transport of agents from nose to brain	24
2.3	Mucoadhesive Delivery Systems	26
2.3.1	Introduction	26
2.3.2	Nasal mucoadhesive drug delivery system	27
2.3.3	Chitosan as a mucoadhesive material	28
2.3.3a	Applications in Pharmaceutical Industry	29
2.3.4	Carbopol as a mucoadhesive material	31
2.3.4a	Applications in Pharmaceutical Industry	32
2.4	Mucoadhesive microspheres	33
2.5	Thermoreversible gels	36
2.6	Sumatriptan succinate profile	39
2.6.1	Introduction	39
2.6.2	Description	39
2.6.2.1	Chemical Name	39
2.6.2.2	Structural Formula	39
2.6.2.3	Molecular formula	39
2.6.2.4	Molecular Weight	39
2.6.2.5	Appearance and colour	39
2.6.3	Physicochemical Properties	39
2.6.3.1	Solubility	39

2.6.3.2	Melting point	39
2.6.3.3	pH	39
2.6.3.4	Partition Coefficient	39
2.6.3.5	Ultraviolet and visible spectrum	39
2.6.4	Mechanism of action	39
2.6.5	Pharmacokinetics	40
2.6.6	Metabolism	40
2.6.7	Toxicology	41
2.6.8	Indications	41
2.6.9	Contraindications	41
2.6.10	Dosage and administration	42
2.6.11	Analytical profile	42
2.7	References	46

SECTION II Analytical methods and permeation mechanism

Chapter 3	Analytical methods	
3a	Estimation of Sumatriptan Succinate Using UV-Visible Spectroscopy	56
3a.1	Experimental	56
3a.1.1	Reagents and solutions	56
3a.1.2	Preparation of calibration curve	56
3a.1.3	Stability and selectivity	57
3a.1.4	Accuracy and precision	57
3a.2	Results and Discussion	70
3b	Estimation of Sumatriptan Succinate Using HPLC With UV-Detection In Biological Samples	72
3b.1	Introduction	72
3b.2	Instrumentation	72
3b.3	Reagents	73
3b.4	Experimental	73
3b.4.1	Blood collection, CSF collection and brain tissue preparation	73
3b.4.2	Preparation of calibration and validation standards	73
3b.4.3	Extraction procedure for plasma samples	74
3b.4.4	Preparation procedure for CSF samples	74
3b.4.5	Extraction procedure for brain samples	74
3b.4.6	Chromatographic conditions	75
3b.4.7	Method validation procedures	75
3b.5	Results and discussion	75
3c	Estimation of Glutaraldehyde	86
3c.1	Experimental	86
3c.1.1	Reagents and solution	86
3c.1.2	Preparation of calibration curve	86
3c.1.3	Selectivity	87
3c.2	Results and Discussion	87
3d	References	89

Chapter 4	<i>In-vitro</i> permeation mechanism of sumatriptan succinate across sheep nasal mucosal membrane	
4.1	Introduction	91
4.2	Experimental	92
4.2.1	<i>In-vitro</i> Permeation Studies	92
4.2.2	Permeability coefficient	93
4.2.3	Statistical analysis	93
4.3	Results and Discussion	94
4.4	Conclusion	98
4.5	References	99
SECTION III	Preparation, optimization, evaluation and stability of formulations	
Chapter 5	Microspheres	
5a	Chitosan glutamate microspheres	100
5a.1	Introduction	100
5a.2	Experimental	101
5a.2.1	Preparation of chitosan glutamate microspheres by emulsification crosslinking method	101
5a.2.2	% Entrapment efficiency	101
5a.2.3	Determination of residual glutaraldehyde	101
5a.2.4	Particle size analysis	102
5a.2.5	Evaluation of Mucoadhesive Strength	102
5a.2.6	<i>In Vitro</i> Permeation Studies	103
5a.2.7	Histopathological evaluation of mucosa	104
5a.2.8	Angle of repose	104
5a.2.9	Morphology Analysis	104
5a.2.10	FTIR studies	104
5a.2.11	Stability studies	104
5a.3	Factorial Design and Desirability Function	105
5a.4	Results and Discussion	107
5a.5	Conclusion	126
5b	Carbopol microspheres	127
5b.1	Optimization of spray drying process for carbopol microspheres	127
5b.1.1	Introduction	127
5b.1.2	Experimental	128
5b.1.2.1	Carbopol microsphere preparation	128
5b.1.2.2	Experimental Conditions	128
5b.1.2.3	Characterization of Spray-Dried Samples	130
5b.1.3	Results and Discussion	131
5b.2	Sumatriptan succinate loaded carbopol microspheres	138
5b.2.1	Introduction	138
5b.2.2	Experimental	138
5b.2.2.1	Preparation of microspheres	138
5b.2.2.2	Characterization of the microspheres	139

A.	Production Yield	139
B.	Drug loading	139
C.	Particle size analysis	139
D.	Evaluation of Mucoadhesive Strength	139
E.	In Vitro Permeation Studies	139
F.	Statistical analysis	139
G.	Histopathological evaluation of mucosa	139
H.	Angle of repose	140
I.	Morphology Analysis	140
J.	Infrared spectroscopy	140
K.	Stability studies	140
5b.2.3	Results and Discussion	140
5b 2.4	Conclusion	151
5c	References	152
Chapter 6	Thermoreversible gels	
6 1	Introduction	155
6.2.	Preparation methods	156
6.2.1.	Preparation of pluronic F-127 gels	156
6.2.2.	Preparation of mixed gels of pluronic F-127 and carbopol 934P	157
6.2.3.	Preparation of mixed gels of pluronic F-127 and chitosan glutamate	157
6 3.	Characterization of formulations	157
6 3.1.	Measurement of gelation temperature by visual inspection	157
6 3.2.	Gelling temperature determination by rheological method	158
6.3.3.	Evaluation of the mucoadhesive strength	158
6 3.4.	<i>In vitro</i> permeation studies	159
6.3.5.	Histopathological evaluation of mucosa	159
6.3 6.	Statistical Analysis	159
6.3.7	Stability Studies	159
6.4.	Results and Discussion	160
6.4.1.	Pluronic F-127 gels	160
6.4.2.	Mixed gels of pluronic F-127 and carbopol 934P	171
6.4.3.	Mixed gels of pluronic F-127 and chitosan glutamate	179
6 5	References	187
SECTION IV	In vivo studies in rat model-Pharmacokinetic study, Pharmacodynamic study and Haemodynamic study	
Chapter 7	Pharmacokinetic study of formulations in rat	
7.1	Introduction	190
7.2	Experimental	191
7 2.1	Pharmacokinetic study	191
7 2.2	Data analysis	192
7.2.3	Statistical Analysis	193
7.3	Results and Discussion	194
7.4	Conclusion	201
7.5	References	203

Chapter 8	Pharmacodynamic study of formulation in rat migraine model	
8.1	Introduction	204
8.2	Experimental	206
8.2.1	Standardization of Migraine Model and Pharmacodynamic Study in Rat	206
8.2.2	Estimation of CGRP by Enzyme Immunoassay Kit	206
8.2.3	Statistical Analysis	207
8.3	Result and Discussion	207
8.4	Conclusion	212
8.5	References	213
Chapter 9	Haemodynamic study in rat	
9.1	Introduction	216
9.2	Experimental	216
9.3	Results and Discussion	217
9.4	Conclusion	224
9.5	References	225
SECTION V	Summary and conclusion	
Chapter 10	Summary and conclusion	226
Publications and Presentations		VIII